AU2007312437C1 - Method for generating active antibodies against a resistance antigen, antibodies obtained by said method and their uses - Google Patents

Method for generating active antibodies against a resistance antigen, antibodies obtained by said method and their uses Download PDF

Info

Publication number
AU2007312437C1
AU2007312437C1 AU2007312437A AU2007312437A AU2007312437C1 AU 2007312437 C1 AU2007312437 C1 AU 2007312437C1 AU 2007312437 A AU2007312437 A AU 2007312437A AU 2007312437 A AU2007312437 A AU 2007312437A AU 2007312437 C1 AU2007312437 C1 AU 2007312437C1
Authority
AU
Australia
Prior art keywords
antibody
tumor
tumoral
antibodies
sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007312437A
Other languages
English (en)
Other versions
AU2007312437B2 (en
AU2007312437A1 (en
Inventor
Liliane Goetsch
Alexandra Jouhanneaud
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Publication of AU2007312437A1 publication Critical patent/AU2007312437A1/en
Publication of AU2007312437B2 publication Critical patent/AU2007312437B2/en
Application granted granted Critical
Publication of AU2007312437C1 publication Critical patent/AU2007312437C1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2007312437A 2006-09-28 2007-09-27 Method for generating active antibodies against a resistance antigen, antibodies obtained by said method and their uses Ceased AU2007312437C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR06/08514 2006-09-28
FR0608514A FR2906533B1 (fr) 2006-09-28 2006-09-28 Procede de generation d'anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations
PCT/EP2007/060243 WO2008046724A1 (en) 2006-09-28 2007-09-27 Method for generating active antibodies against a resistance antigen, antibodies obtained by said method and their uses

Publications (3)

Publication Number Publication Date
AU2007312437A1 AU2007312437A1 (en) 2008-04-24
AU2007312437B2 AU2007312437B2 (en) 2014-01-23
AU2007312437C1 true AU2007312437C1 (en) 2014-04-10

Family

ID=38164542

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007312437A Ceased AU2007312437C1 (en) 2006-09-28 2007-09-27 Method for generating active antibodies against a resistance antigen, antibodies obtained by said method and their uses

Country Status (21)

Country Link
US (2) US8241646B2 (https=)
EP (4) EP2497491B1 (https=)
JP (1) JP5774276B2 (https=)
KR (1) KR101504770B1 (https=)
CN (1) CN101516394B (https=)
AR (1) AR063061A1 (https=)
AU (1) AU2007312437C1 (https=)
BR (1) BRPI0717246A2 (https=)
CA (1) CA2663561A1 (https=)
FR (1) FR2906533B1 (https=)
IL (1) IL197790A (https=)
MA (1) MA30954B1 (https=)
MX (1) MX2009003245A (https=)
NO (1) NO20091613L (https=)
NZ (1) NZ576420A (https=)
RU (1) RU2515904C2 (https=)
TN (1) TN2009000102A1 (https=)
TW (1) TWI516276B (https=)
UA (1) UA102812C2 (https=)
WO (1) WO2008046724A1 (https=)
ZA (1) ZA200902697B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
CU23736A1 (es) * 2009-05-04 2011-11-15 Centro Inmunologia Molecular Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso
WO2011004899A1 (en) * 2009-07-06 2011-01-13 Takeda Pharmaceutical Company Limited Cancerous disease modifying antibodies
US20120282211A1 (en) * 2009-11-24 2012-11-08 Carnegie Mellon University Antibodies and conjugates for modulators of angiogenesis
EP2635602B1 (en) 2010-11-03 2016-09-07 Argen-X Nv Anti c-met antibodies
US9255595B2 (en) * 2011-04-29 2016-02-09 Bae Systems Information And Electronic Systems Integration Inc. Optical dome bezel
US9926364B2 (en) 2011-11-03 2018-03-27 Argen-X N.V. Chimeric human-llama antigens and methods of use
US9657098B2 (en) 2013-03-15 2017-05-23 Intrinsic Lifesciences, Llc Anti-hepcidin antibodies and uses thereof
TW201613615A (en) 2014-06-30 2016-04-16 Academia Sinica Antagonists for interleukin-17 receptor B (IL-17RB) and its ligand IL-17B for cancer therapy
AU2015321462B2 (en) 2014-09-22 2020-04-30 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
AR105553A1 (es) * 2015-04-27 2017-10-18 Pf Medicament Anticuerpo del receptor del factor 1 del crecimiento similar a insulina (igf-1r) y su utilización para diagnosticar cáncer
TWI740824B (zh) * 2015-04-27 2021-10-01 法商皮爾法伯製藥公司 新穎的ｉｇｆ－１ｒ抗體及其用於癌症診斷之用途（一）
EP3334757A4 (en) * 2015-08-14 2019-04-03 Merck Sharp & Dohme Corp. ANTI-Tigit ANTIBODY
US10981991B2 (en) * 2015-09-29 2021-04-20 Shanghai Zhangjiang Biotechnology Co., Ltd. PD-1 antibodies and uses thereof
GB2547179A (en) * 2015-10-26 2017-08-16 Quethera Ltd Genetic construct
WO2025111382A2 (en) * 2023-11-21 2025-05-30 Board Of Regents, The University Of Texas System Anti-lamp5 antibodies, engineered immune cells expressing anti-lamp5 antibodies, and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0214640A2 (en) * 1985-09-11 1987-03-18 Japanese Foundation For Cancer Research Monoclonal antibody in relation to drug-resistant cancers and production thereof
WO1993025700A1 (en) * 1992-06-17 1993-12-23 Istituto Superiore Di Sanita' Monoclonal antibodies to glycoprotein p

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
KR950700061A (ko) * 1992-02-06 1995-01-16 스티븐 엘. 네스비트 테트라아릴에틸렌에 의한 다중 약물 내성의 역전(reversal of multi -drug resistance by tetraarylethylenes)
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5503984A (en) * 1993-04-13 1996-04-02 Health Research, Inc. Hybridoma producing monoclonal antibody F4 which specifically binds to multidrug resistant P-glycoprotein and assays for detection of P-glycoprotein
WO1999066027A1 (en) * 1998-06-15 1999-12-23 The Research Foundation Of State University Of New York Monoclonal antibodies that recognize antigens associated with tumor metastasis
US7303760B2 (en) 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
DE60312639T2 (de) 2002-01-18 2007-11-29 Pierre Fabre Médicament Antikörper gegen igf-ir und ihre verwendungen
US20040121965A1 (en) 2002-09-20 2004-06-24 Wyeth Holdings Corporation Method of treating resistant tumors
WO2005035721A2 (en) * 2003-10-08 2005-04-21 Ebioscience Native immunoglobulin binding reagents and methods for making and using same
WO2005077385A2 (en) 2004-02-18 2005-08-25 Gpc Biotech Ag Methods for treating resistant or refractory tumors
EP1742060A1 (en) * 2005-01-24 2007-01-10 DIGILAB BioVisioN GmbH TIF1-beta peptides and nucleic acids for diagnosis and therapy of cancer and colorectal cancerous disorders.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0214640A2 (en) * 1985-09-11 1987-03-18 Japanese Foundation For Cancer Research Monoclonal antibody in relation to drug-resistant cancers and production thereof
WO1993025700A1 (en) * 1992-06-17 1993-12-23 Istituto Superiore Di Sanita' Monoclonal antibodies to glycoprotein p

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Sinkovics, J. and Horvath, J. 2000 "Vaccination against human cancers (Review)". Int. J. Oncol. vol.16, pp. 81-96 *

Also Published As

Publication number Publication date
ZA200902697B (en) 2010-04-28
US8808667B2 (en) 2014-08-19
CN101516394B (zh) 2014-07-30
WO2008046724A1 (en) 2008-04-24
EP2491945B1 (en) 2016-12-07
NO20091613L (no) 2009-06-26
CA2663561A1 (en) 2008-04-24
TN2009000102A1 (en) 2010-08-19
AR063061A1 (es) 2008-12-23
EP2497491B1 (en) 2017-03-01
US20100146650A1 (en) 2010-06-10
EP2491945A1 (en) 2012-08-29
UA102812C2 (ru) 2013-08-27
KR101504770B1 (ko) 2015-03-20
TW200822934A (en) 2008-06-01
MX2009003245A (es) 2009-07-07
NZ576420A (en) 2012-05-25
JP5774276B2 (ja) 2015-09-09
EP2494984B1 (en) 2017-01-04
FR2906533A1 (fr) 2008-04-04
AU2007312437B2 (en) 2014-01-23
RU2009114682A (ru) 2010-11-20
EP2497491A1 (en) 2012-09-12
MA30954B1 (fr) 2009-12-01
IL197790A (en) 2016-10-31
BRPI0717246A2 (pt) 2013-10-08
EP2491945B9 (en) 2017-03-08
HK1131063A1 (en) 2010-01-15
US20130028835A1 (en) 2013-01-31
KR20090057469A (ko) 2009-06-05
JP2010504743A (ja) 2010-02-18
EP2081592A1 (en) 2009-07-29
RU2515904C2 (ru) 2014-05-20
TWI516276B (zh) 2016-01-11
FR2906533B1 (fr) 2013-02-22
EP2081592B1 (en) 2016-01-13
EP2494984A1 (en) 2012-09-05
US8241646B2 (en) 2012-08-14
AU2007312437A1 (en) 2008-04-24
IL197790A0 (en) 2011-08-01
CN101516394A (zh) 2009-08-26

Similar Documents

Publication Publication Date Title
AU2007312437C1 (en) Method for generating active antibodies against a resistance antigen, antibodies obtained by said method and their uses
KR101671039B1 (ko) 항 ｃｘｃｒ4 항체 및 그들의 암의 치료를 위한 용도
CN101535344B (zh) 新型抗增殖抗体
KR20110010708A (ko) 암을 치료하는데 사용되는 새로운 항체들
WO2017214547A1 (en) Anti-tnfrsf25 antibodies
US20030180799A1 (en) Antibodies against plasma cells
HK1131063B (en) Method for generating active antibodies against a resistance antigen, antibodies obtained by said method and their uses

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 24 DEC 2013 .

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 24 DEC 2013

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired